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AbstrAct
background: The aim of the study was to evaluate analysis criteria for the identification of the presence of rectal gas during 
volumetric modulated arc therapy (VMaT) for prostate cancer patients by using electronic portal imaging device (epID)-based 
in vivo dosimetry (IVD).
Materials and methods: all measurements were performed by determining the cumulative epID images in an integrated 
acquisition mode and analyzed using perFracTION commercial software. systematic setup errors were simulated by moving 
the anthropomorphic phantom in each translational and rotational direction. The inhomogeneity regions were also simulated 
by the I’mrT phantom attached to the Quasar phantom. The presence of small and large air cavities (12 and 48 cm3) was con-
trolled by moving the Quasar phantom in several timings during VMaT. sixteen prostate cancer patients received epID-based 
IVD during VMaT.
results: In the phantom study, no systematic setup error was detected in the range that can happen in clinical (< 5-mm and 
< 3 degree). The pass rate of 2% dose difference (DD2%) in small and large air cavities was 98.74% and 79.05%, respectively, 
in the appearance of the air cavity after irradiation three quarter times. In the clinical study, some fractions caused a sharp 
decline in the DD2% pass rate. The proportion for DD2% < 90% was 13.4% of all fractions. rectal gas was confirmed in 11.0% 
of fractions by acquiring kilo-voltage X-ray images after the treatment. 
conclusions: Our results suggest that analysis criteria of 2% dose difference in epID-based IVD was a suitable method for 
identification of rectal gas during VMaT for prostate cancer patients. 
Key words: in vivo dosimetry (IVD); electronic portal imaging device (epID); prostate cancer; rectal gas; patient-specific quality 
assurance (Qa)
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High-precision radiation therapy, such as in-
tensity modulated radiation therapy (IMRT) and 
volumetric modulated arc therapy (VMAT), can 
be used to create a steep dose gradient and com-
plement dose distribution [1, 2]. These techniques 
enable the target dose to be increased and the organ 
at risk (OAR) dose to be decreased. Treatment of 
prostate cancer patients has often used IMRT and 
VMAT, resulting in better tumor control and re-
duced toxic effects in the bladder and rectum [3–5]. 
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However, a steeper dose gradient, more complex 
dose distribution, and a smaller planning target vol-
ume (PTV) margin may cause geometrical uncer-
tainties, such as interfractional and intrafractional 
setup variation and organ movement, that displace 
the target from the treatment field. Image-guided 
radiation therapy (IGRT) is used to aid precise dose 
delivery to the target. This method enables the in-
terfractional setup variation to be reduced as much 
as possible. 
Intrafractional organ movement in prostate can-
cer treatment has been studied over the past 20 
years [6, 7]. Some studies have used magnetic reso-
nance imaging (MRI) to monitor intrafractional 
prostate and rectum movement in real time during 
treatment [6–11]. These studies suggest that rectal 
gas causes a distended rectum, thereby displacing 
the prostate. This indicates that rectal gas can be 
used as an indicator of intrafractional rectum and 
prostate movement. Moreover, rectal gas causes an 
increase in the inhomogeneity of the density of ma-
terials in the beam path, altering the dose distribu-
tion and causing the appearance of hot spot in the 
rectal wall and prostate. It is therefore important to 
determine the presence of rectal gas during treat-
ment.
Several studies reported that an electronic por-
tal imaging device (EPID) had usefulness in the 
dose verifications for pre-treatment [12, 13]. EP-
ID-based in vivo dosimetry (IVD) is one of the 
patient-specific quality assurance (QA) methods 
and it is widely used to detect major treatment er-
rors during radiation therapy [14–22]. EPID-based 
IVD is also a real-time verification system that is 
easy to use and does not require additional setup 
time for IMRT and VMAT. This system ensures 
safety and accuracy on a daily basis by measuring 
and analyzing the beam penetrating the patient’s 
body during treatment in the integrated acquisition 
mode. Such a verification system is an additional 
tool that can help reveal major treatment errors 
such as intrafractional patient and organ move-
ment during IMRT and VMAT. However, little has 
been done to identify the presence of rectal gas 
using EPID-based IVD in VMAT for prostate can-
cer patients. We hypothesized that inhomogeneity 
regions such as those with rectal gas can be changed 
owing to the beam passing through the patient’s 
body and detected using EPID-based IVD. Hence, 
the aim of this study was to evaluate analysis cri-
teria for the identification of the presence of rectal 
gas when EPID-based IVD is used in VMAT for 
prostate cancer patients. A phantom study identi-
fied the magnitude of error in EPID-based IVD 
when setup error and rectal gas in the range that 
can happen in a clinical study occurs. In a clinical 
study, the feasibility of using EPID-based IVD to 
detect rectal gas was assessed based on the results 
of the phantom study.
Material and methods
This research consists of three parts: two phan-
tom studies and one clinical study. Settings that are 
common among the three studies are described in 
the following section, while settings specific to each 
study are specified in the section after that.
common settings
In the phantom and clinical studies, all computed 
tomography (CT) scans were performed using a GE 
Dual Energy instrument (64 slices, General Electric 
Co., Waukesha, WI). The parameters of the CT im-
ages were 2.0-mm slice thickness and 500-mm field 
of view with dimensions of 512 × 512 pixels. All the 
CT images were transferred to an Eclipse planning 
system (version 13.7.14, Varian Medical Systems, 
Palo Alto, CA). In Eclipse, all plans were calculated 
with the analytical anisotropic algorithm for dose 
calculation with inhomogeneity corrections, and 
exported to the PerFRACTION software (version 
1.7.3, Sun Nuclear Corporation, Melbourne, FL) as 
DICOM files.
PerFRACTION, which uses GPU-accelerated 
convolution/superposition algorithm (Sun Nu-
clear Dose Calculator) and is independent of the 
Eclipse planning system, is a commercial software 
for pre- and on-treatment patient-specific QA by 
using the EPID images. This system was used for 
the on-treatment patient-specific QA (Fraction N) 
in our study. The feature of PerFRACTION is au-
tomatic retrieval of the acquired new EPID im-
ages and comparison of these images against the 
baseline images through various user-defined tests 
including gamma analysis, percentage dose dif-
ference (DD), and distance-to-agreement (DTA) 
for any criteria and threshold. The beam model of 
PerFRACTION is created by Sun Nuclear Corpo-
ration following the data of percent depth dose, 
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output factor, and profile in reference condition and 
VMAT planning often used in our institute.
EPID-based IVD was performed using a linear 
accelerator, TrueBeam STx (Varian Medical Sys-
tems) equipped with a gantry-mounted on-board 
imager and an EPID, aS1200 PortalVision image 
detector (Varian Medical Systems). The square 
pixels of the EPID had a side length of 0.34 mm, 
yielding a total area of approximately 40 × 40 cm2 
(1190 × 1190 pixels). All EPID images were ob-
tained in the integrated acquisition mode, and 
a source-to-imager distance of 160 cm was used for 
both the stationary and rotational settings. The lin-
ear accelerator was equipped with high definition 
multileaf collimators (MLCs), the widths of which 
were 2.5 mm for the first 32 leaves from the central 
point and 5 mm for the rest.
specific settings
First phantom study
To assess the detectability of a setup error in 
EPID-based IVD, an anthropomorphic phantom 
(Kyoto Kagaku, Japan) was used (Fig. 1A). In CT 
images of the anthropomorphic phantom, the 
prostate was contoured as the target volume, while 
the rectum, bladder, and small and large bow-
els were contoured as OARs. A single-arc VMAT 
plan using 2 Gy fractions with 6-MV photons was 
created for target contouring. The plans were op-
timized to deliver the mean of the prescribed dose 
to the PTV.
To acquire baseline measurements, the anthro-
pomorphic phantom was correctly set up by using 
cone-beam computed tomography (CBCT) image 
guidance and irradiated while the cumulative EPID 
images were acquired. Systematic setup errors were 
simulated by shifting the phantom by 1, 3, 5, and 
10-mm in the anterior-posterior (AP), superior-in-
ferior (SI), and left-right (LR) directions. Angular 
setup errors were also simulated by shifting the 
phantom by 1° and 3° in the pitch, roll, and yaw 
rotations. The EPID images were captured for each 
condition.
second phantom study
To assess the detectability of inhomogeneity re-
gions in the rectum in EPID-based IVD, an I’mRT 
phantom comprised of a body phantom (IBA 
Dosimetry, Schwarzenbruck, Germany) was used 
(Fig. 1B). The mock prostate structure set down-
loaded from AAPM TG119 was registered on CT 
images of the I’mRT phantom with MIM Maes-
tro (MIM Software Inc., OH, USA). A single-arc 
VMAT plan using 2 Gy fractions with 6-MV pho-
tons was optimized to deliver the mean of the pre-
scribed dose to the PTV. 
To acquire baseline measurements, the I’mRT 
phantom was correctly set up by using CBCT im-
Figure 1. A. The anthropomorphic phantom for the verification of systematic setup error. b. The I’mrT phantom for the 
verification of inhomogeneity region. c. The position of the air cavity in the I’mrT phantom. D. The programmable motion 
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age guidance and irradiated while the cumulative 
EPID images were acquired. Multiple-size air cavi-
ties which simulated rectal gas were created in the 
I’mRT phantom. We prepared the air cavities with 
diameters of 2 and 4 cm because the mean rectal 
diameter in clinical study was about 3 cm. Each air 
cavity, with volume of either 12 (2 × 2 × 3) cm3 or 48 
(4 × 4 × 3) cm3 was created 1 cm below the middle 
of the I’mRT phantom (Fig. 1C). 
Rectal gas may occur during irradiation, so we 
established a system controlling the time when 
gas is produced in the I’mRT phantom. The I’mRT 
phantom was attached next to a programmable 
motion platform (Quasar Respiratory Motion 
Platform; Modus Medical Devices Inc., London, 
ONT, Canada) (Fig. 1D). At the time when gas 
was scheduled to occur, some blocks attached to 
the programmable motion platform were pulled, 
and air cavities of volumes 12 (2 × 2 × 3) cm3 and 
48 (4 × 4 × 3) cm3 were created 1 cm below the 
middle of the I’mRT phantom. The timing of when 
the air cavities occurred was controlled by mov-
ing the motion phantom during irradiation. Three 
timings were prepared and followed: at 25% (T25%), 
50% (T50%), and 75% (T75%) of the single-arc irradia-
tion time. The I’mRT phantom with small and large 
air cavities were also measured during single-arc 
VMAT from beginning to end (T0%). The EPID im-
ages were captured for each condition with I’mRT 
phantom with each air cavity.
clinical study
From August 2017 to May 2018, 16 patients 
with histologically proven low-, intermediate- or 
high-risk localized prostate cancer underwent 
VMAT at the Osaka International Cancer Institute. 
The patients were aged 65 to 81 years (median: 77 
years). All patients were required to empty their 
bladder and evacuate their bowels 1 h before the 
CT simulation. For the CT simulation, they were 
immobilized using the Vac-Lock Cushion (Civco 
Medical Solutions, Iowa, USA) for the pelvis region 
and they were given leg support and a pillow. Af-
ter the immobilization devices were fixed, a treat-
ment-planning CT scan was performed. If the rec-
tum was deemed too large, the patients had to 
retake the scan after the rectum was emptied. After 
CT simulation, the target volumes and OARs (i.e., 
the rectum, bladder, and small and large bowels) 
were contoured by radiation oncologists following 
the recommendations in Reports 50 and 62 of the 
International Commission on Radiation Units [23, 
24]. All the patients were treated with 6-MV pho-
tons using single-arc VMAT and received doses of 
74 Gy in 37 fractions or 78 Gy in 39 fractions. The 
doses were prescribed at mean dose for the PTV.
All the patients received daily soft tissue regis-
tration, which was performed using CBCT, and 
planning CT in a 6 degree of freedom couch. If the 
rectum was full of rectal gas near the prostate, the 
patient was encouraged to evacuate their bowels 
and registration was performed again. All the pa-
tients received VMAT while the cumulative EPID 
images were acquired in all the sessions. The EPID 
image in the first treatment session was defined 
as the baseline image. After treatment, all the pa-
tients were subjected to registration using a pair of 
orthogonal kilo-voltage X-ray images and DRR to 
determine the presence of rectal gas.
Data analysis
Two-dimensional (2D) analysis in PerFRAC-
TION was performed using gamma and DD meth-
ods. Analysis criteria of 3%/3 mm, 2%/2 mm, and 
1%/1 mm, and 3%, 2%, and 1%, respectively, were 
used for the gamma and DD analysis above 10% of 
maximum signal threshold. The presence of rectal 
gas after treatment was confirmed via offline re-
views (Varian Medical Systems).
results
phantom study
Single-arc VMAT was performed on the an-
thropomorphic phantom to assess the effect of sys-
tematic setup error on EPID-based IVD, and the 
results are shown in Table 1. The gamma analysis 
revealed > 95% in shifts of the AP and LR direc-
tions, and pitch, roll, and yaw rotations (Fig. 2). The 
pass rates of the DD were the same as those of the 
gamma analysis in the AP and LR directions of less 
than 5-mm shift, and pitch, roll, and yaw rotations. 
In the SI direction, the pass rates for the DD of 1% 
in more than 3-mm shifts, and for the gamma of 
1%/1 mm and for the DD of 2% in more than 5-mm 
shifts were less than 95%. 
Table 2 illustrates the effect of the presence of 
inhomogeneity regions on EPID-based IVD in 
I’mRT phantom with an air cavity. A larger air cav-
ity resulted in decreased pass rates for the gamma 
Shoki Inui et al. evaluation of two-dimensional electronic portal imaging device during VMaT
285https://journals.viamedica.pl/rpor
analysis of 1%/1 mm and the DD of 3%, 2%, and 
1%. A longer presence time for inhomogeneity 
regions during irradiation resulted in decreased 
pass rates for the gamma analysis of 1%/1 mm 
and the DD of 3% of a large air cavity, and for the 
DD of 2% and 1% of large and small air cavities. 
However, all criteria of the gamma analysis were 
more than 90% pass rates for all phases in a small 
air cavity (Fig. 3). 
Based on these results of phantom studies, we 
evaluated the results of the clinical study by using 
the DD of 2% (DD2%). At T75%, the air cavity ap-
peared after 75% of the irradiation time and stayed 
for 25% of the irradiation time. Because the mean 
Figure 2. The comparison of the gamma and dose difference (DD) analysis in systematic setup error simulated by shifting the 
anthropomorphic phantom by 5 mm in the ap direction. The epID images of expected dose are baseline. Dose profile X and Y 
are horizontal and vertical lines in the gamma index and difference
table 1. systematic setup error simulated by shifting anthropomorphic phantom
Direction Shift
Gamma (%) DD (%)
3%/3 mm 2%/2 mm 1%/1 mm 3% 2% 1%
No shift 100.00 100.00 100.00 100.00 100.00 100.00
ap + 1 mm 99.99 99,98 99.98 99.98 99.98 99.95
+ 3 mm 99.99 99.98 99.98 99.98 99.98 99.83
+ 5 mm 99.99 99.98 99.96 99.98 99.98 97.05
+ 10 mm 99.99 99.95 99.33 99.87 98.77 79.59
sI + 1 mm 99.99 99.98 99.56 99.93 98.85 96.49
+ 3 mm 99.99 99.01 96.84 97.25 95.77 89.77
+ 5 mm 99.98 97.73 94.80 95.29 93.08 80.31
+ 10 mm 99.85 95.74 89.87 90.59 85.28 69.17
Lr + 1 mm 99.99 99.98 99.98 99.99 99.98 99.97
+ 3 mm 99.99 99.98 99.95 99.99 99.87 97.03
+ 5 mm 99.99 99.98 99.65 99.84 98.63 94.46
+ 10 mm 99.97 99.76 96.98 97.44 94.28 85.88
pitch + 1° 100.00 100.00 100.00 100.00 100.00 99.95
+ 3° 100.00 100.00 100.00 100.00 100.00 99.87
roll + 1° 100.00 100.00 100.00 100.00 100.00 99.86
+ 3° 100.00 100.00 100.00 100.00 100.00 99.77
Yaw + 1° 100.00 100.00 100.00 100.00 100.00 99.21
+ 3° 100.00 100.00 100.00 100.00 100.00 99.17
DD — dose difference; ap — anterior-posterior; sI — superior-inferior; Lr — left-right
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value of DD2% at T75% in the large and small air 
cavities was about 90%, DD2% < 90% was defined 
as the possibility of the rectum of being full of rectal 
gas during irradiation.
clinical study
A total of 614 fractions from 16 patients were 
subjected to EPID-based IVD during VMAT. 
Among the total, 25 fractions were irretrievable 
table 2. Inhomogeneity regions simulated using the I’mrT phantom with air cavity
Air cavity [cm3] Method Criteria T0% T25% T50% T75% T100%
12 (2 × 2 × 3)
Gamma (%)
3%/3 mm 99.98 99.98 99.99 99.99 100.00
2%/2 mm 98.79 99.97 99.98 99.98 100.00
1%/1 mm 91.55 92.29 97.96 98.61 100.00
DD (%)
3% 92.46 92.78 99.98 99.99 100.00
2% 81.63 84.30 96.14 98.74 100.00
1% 61.32 74.90 79.37 86.09 100.00
48 (4 × 4 × 3)
Gamma (%)
3%/3 mm 99.73 99.82 99.99 99.99 100.00
2%/2 mm 96.27 98.01 99.45 99.98 100.00
1%/1 mm 80.91 87.98 93.80 96.90 100.00
DD (%)
3% 69.76 80.52 83.19 88.89 100.00
2% 59.03 60.97 73.86 79.05 100.00
1% 40.44 46.98 55.11 56.50 100.00
The appearance of air cavity was controlled by moving the motion phantom after quarter (T25%), half (T50%), and three to four times (T75%) during one-arc VMaT. 
The I’mrT phantom with small and large air cavities during VMaT from beginning to end were also measured (T0%). None of air cavity was also measured (T100%); 
DD — dose difference
Figure 3. The comparison of the gamma and dose difference (DD) analysis in inhomogeneity regions simulated using the 
I’mrT phantom which had a small air cavity with or without the programmable motion platform movement. at T0%, the air 
cavity had stayed in the irradiation time from beginning to end. at T50%, the air cavity appeared after 50% of the irradiation 
time and had stayed for 50% of the irradiation time. The epID images of expected dose are baseline. Dose profile X and Y are 
horizontal and vertical lines in the gamma index and difference
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because of a defect in data transmission. Figure 4 
illustrates the daily variation in the pass rate in the 
EPID-based IVD for three representative patients. 
There was almost no change in the pass rate for 
some patients, but the pass rate changed for oth-
ers in about one to three fractions. Figure 5 shows 
an example of a fraction with full rectal gas after 
clinical treatment displayed using PerFRACTION 
software. Some fractions could be used to confirm 
the location of rectal gas during treatment via the 
analysis of EPID images the same as Figure 5. Ta-
ble 3 summarizes the analysis results of the clini-
cal study for EPID-based IVD for prostate cancer. 
The results of nearly 90% of the fractions were 
DD2%>90% in all the patients. The average DD2% 
value of the fractions with an empty rectum and 
a rectum full of rectal gas after irradiation were 
96.12% and 86.13%. Moreover, the proportion of 
DD2% < 90% indicated that there were more frac-
tions with a rectum full of rectal gas than with an 
empty rectum (Fig. 6).
Discussion
Several studies have reported that EPID-based 
IVD can be used to identify major treatment errors 
such as intrafractional patient and organ movement 
[15–22]. However, these studies did not clearly 
table 3. results of clinical study for epID-based IVD for 
prostate cancer
All patients (n = 16, 589 fractions) Fraction (%)
DD2% ≥ 90% 510 (86.59)
DD2% < 90% 79 (13.41)
empty rectum after irradiation 524 (88.96)
rectum full of rectal gas after irradiation 65 (11.04)
DD2% — dose difference criteria 2%
Figure 6. Dose difference distribution for the presence or 
absence of rectal gas after irradiation in a clinical study; 
DD2% — dose difference criteria 2%
Figure 4. The daily transition of the pass rate in epID-based 




Figure 5. example of a fraction appeared rectal gas during treatment in a clinical study (Fraction 9 in patient 10). sagittal view 
of kV images (A) before, (b) after irradiation, with pTV, bladder, and rectum contoured in red, blue, and brown. c. The result of 
the epID image analyzed by DD2% in clinical study. The epID image of expected dose is that of Fraction 1 in patient 9. Dose 
profile X and Y are horizontal and vertical lines in the gamma index and difference
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show the cause of treatment errors identified by the 
EPID images. In the prostate cancer patients, the 
main cause of these was patient body movement 
and the occurrence of rectal gas during treatment. 
Therefore, to the best of our knowledge, this study 
is the first one to focus on the detectability of setup 
error and rectal gas during VMAT for prostate can-
cer patients by using EPID-based IVD. 
In terms of the analysis method, previous reports 
suggested that the DTA component of the gamma 
method masked the setup error in the EPID im-
ages of individual IMRT fields [22, 25]. Our results 
confirmed these findings in VMAT. In the phantom 
study, the pass rates of gamma method in all criteria 
were more than 90% in a small air cavity (12 cm3), 
but those of DD of 2% and 1% were less than 90%. 
The gamma method could not detect small changes 
unlike the DD method. Therefore, we used the DD 
method for data analysis.
Some researchers proposed that EPID-based 
IVD could be used to successfully detect system-
atic setup errors in the head region [22, 26]. This is 
not in agreement with our findings because no sys-
tematic setup error was detected when simulating 
the anthropomorphic phantom in the range that 
can happen in clinical (< 5 mm and < 3 degree). 
This is because the bone structure and body surface 
in the case of head cancer are more complicated 
than those for prostate cancer. Because the prostate 
is located in the center of the pelvic region, the 
VMAT plan is less subject to changes of the beam 
pass. Moreover, several reports found that system-
atic setup errors were detected in 3-dimensional 
conformal radiotherapy (3DCRT) [15, 26]. This is 
because the dose distribution of the 3DCRT was 
sharper than that of VMAT in the edge of each 
field. Hence, EPID-based IVD is inadequate for 
systematic setup error detection in the VMAT plan 
for the pelvic region. 
However, our study demonstrated that EP-
ID-based IVD is useful for identifying inhomoge-
neity regions in the I’mRT phantom. In the pelvic 
region, an inhomogeneity region is highly sugges-
tive of rectal gas. EPID-based IVD could detect 
small air cavities with a diameter of 2 cm. In addi-
tion, our data indicated chronological changes in 
the air cavity during VMAT. Larger air cavities and 
a longer stop time resulted in decreased pass rates. 
It is suggested that EPID-based IVD is better for 
identifying inhomogeneity regions than detecting 
systematic setup errors. Moreover, the mean rectal 
diameter in our clinical study was 3 cm, which was 
between the sizes of the large and small air cavities 
in the phantom studies. We decided to assess the 
occurrence of rectal gas for DD2% < 90% in the 
clinical study by calculating the mean values of T75% 
in the large and small air cavities on the assumption 
that rectal gas appears during treatment.
We measured and analyzed the EPID images in 
the clinical study to confirm the correlation be-
tween the pass rates and occurrence of rectal gas 
during VMAT. The proportion of DD2% < 90% was 
13.4% for all the patients. Rectal gas was confirmed 
in 11.0% of fractions. Rosario et al. reported that 
the prostate position error was detected in 13.0% of 
fractions by using automatic detection of implant-
ed gold seeds and the imaging application Auto 
Beam Hold (Varian Medical Systems) [27]. This is 
in agreement with our results which demonstrated 
the proportion of rectal-gas-positive cases and the 
decrease in the DD2%. However, the proportion 
of DD2% < 90% and fractions with a rectum full 
of rectal gas after irradiation was only 5.8% in our 
study. There is a possibility that rectal gas goes in 
and out of the rectum during and after irradiation 
because there was no rectal gas before irradiation 
by using X-ray image registration. In addition, the 
proportion of DD2% < 90% in rectal-gas-positive 
cases was larger than that in rectal-gas-negative 
cases, but about 50% of the gas-positive cases had 
DD2% > 90%. This may be because rectal gas ap-
peared from the completion of treatment to the 
acquisition of kV images. Moreover, we did not 
quantify changes in bladder volume in each condi-
tion because the main cause of the decline in DD2% 
was the presence of inhomogeneity regions, accord-
ing to the results of the phantom study. Some stud-
ies reported that EPID-based IVD had effects on 
the detection of rectal gas in 3DCRT for rectal and 
prostate cancer [15, 20]. Woodruff et al. found that 
prostate cancer patients had a lower pass rate than 
other cancer patients for EPID-based IVD, which 
was due to the rectum being filled with rectal gas in 
CBCT scans in the last week of treatment [18]. Col-
lectively, it is proposed that EPID-based IVD can 
indicate the presence of rectal gas during VMAT.
Most of the fraction in DD2% < 90% had not 
the point dose over 5% dose difference, indicat-
ing that patient specific QA was acceptable in our 
study. This is because a large amount of rectal gas 
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causes the point dose over 5% dose difference, 
but we have often stopped the treatment by using 
CBCT images when a large amount of rectal gas 
was detected near the target. However, VMAT 
plan is steeper dose gradient and more compli-
cated dose distribution. Therefore, the occurrence 
of a small amount of rectal gas near the target is 
imprecated in the lower target cover. Connolly et 
al. found that local recurrence was the greatest 
on the rectal side compared to other locations af-
ter radiation therapy for prostate cancer patients 
[28]. One reason for this may be the presence of 
rectal gas during treatment. It is not possible to 
determine the accurate dose for a target because 
the presence of rectal gas can cause changes in the 
beam pass by repeating complicated build up and 
down. Many reports suggest that the presence of 
rectal gas induces intrafractional prostate and rec-
tum movement that prevents accurate treatment 
[6–11]. The presence of rectal gas is the predictor 
of performing accurate treatment. Therefore, it is 
important to identify if rectal gas is present dur-
ing treatment and obtain evidence for accurate 
treatment. EPID-based IVD in VMAT can detect 
the rectal gas and monitor accurate treatment 
in each fraction. It is hoped that the outcome of 
this study will contribute to accurate radiation 
therapy for prostate cancer patients. One of the 
limitations of this study is that we were not able 
to compare the EPID image for the planning CT 
with that in each fraction. This can be used to 
more accurately determine the presence of rectal 
gas in the future.
conclusion
This study clearly demonstrates that analysis cri-
teria of 2% dose difference in EPID-based IVD can 
identify the presence of rectal gas during VMAT 
for prostate cancer patients. It was difficult for EP-
ID-based IVD in VMAT for prostate cancer pa-
tients to detect systematic setup errors of the range 
that can happen in a clinical study.
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